DDInter1824 DDInter1676
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tociliz
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Tocilizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Tocilizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Tocilizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isradipine
Tocilizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dienogest
Tocilizumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Tocilizumab {u} may lead to a major life threatening interaction when taken with {v} Canakinumab
Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Isradipine
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Dienogest
Tocilizumab may lead to a major life threatening interaction when taken with Fingolimod
Tocilizumab may lead to a major life threatening interaction when taken with Canakinumab